Presentation is loading. Please wait.

Presentation is loading. Please wait.

Value Based Drug Development April 21 st, 2015 Moderator: Ellen V. Sigal, PhD Chair & Founder, Friends of Cancer Research 1.

Published byMaximilian Leonard Modified over 9 years ago

Similar presentations

Presentation on theme: "Value Based Drug Development April 21 st, 2015 Moderator: Ellen V. Sigal, PhD Chair & Founder, Friends of Cancer Research 1."— Presentation transcript:

1 Value Based Drug Development April 21 st, 2015 Moderator: Ellen V. Sigal, PhD Chair & Founder, Friends of Cancer Research 1

2 US Spending on Cancer Treatment continues to rise Total costs increased 35% from 2001 - 2011 Prescription drugs are 11.4% of Cancer Treatment Expenditures Drug costs alone rose $8 billion in 10 years, an increase of 500% *Center for Financing, Access, and Cost Trends, AHRQ, Household Component of the Medical Expenditure Panel Survey, 2001 and 2011 2

3 US cost of care can vary widely for routine medical procedures, hospital stays, and cancer drugs Prescription Drug costs - 9% of Total US Healthcare Expenditures Gleevec has had a much higher success rate for patients than many other high cost drugs *Data from International Federation of Health Plans 2013 Comparative Price Report 3

4 Cost Difference for Cancer Patients Receiving Chemotherapy* Patients receiving chemotherapy treatment in a community oncology clinic (COC) had a 20% to 39% lower cost of care, depending on diagnosis, compared with those receiving chemotherapy in the hospital outpatient setting (HOP) *Am J Manag Care. 2015;21(3):e189-e196 4

5 In Summary National Cancer Care Expenditures continue to rise – Costs for routine procedures and cancer care vary substantially – Patients can end up paying more depending on the treatment center – Great potential to address rising costs for utilization of precision medicine and genetic screening (right drug, to the right patient, at the right time) As we discuss value in drug development, cost issues are at the forefront It is important to determine: 1.What does value mean for patients? 2.How the following key components impact patient access, quality of life, and chance of survival: Cost Trends Advances in Innovation Payment Models 5

6 Panelists Richard Schilsky, MD – Chief Medical Officer, ASCO Mace Rothenberg, MD – Senior Vice President and Chief Medical Officer, Pfizer Andrea Stern Ferris – President, LUNGevity Louis J. DeGennaro – President, CEO, Leukemia and Lymphoma Society 6

Download ppt "Value Based Drug Development April 21 st, 2015 Moderator: Ellen V. Sigal, PhD Chair & Founder, Friends of Cancer Research 1."

Similar presentations

THE COMMONWEALTH FUND 1 Bending the Curve: Options for Achieving Savings and Improving Value in Health Spending Cathy Schoen Senior Vice President The.

THE COMMONWEALTH FUND 1 Bending the Curve: Options for Achieving Savings and Improving Value in Health Spending Cathy Schoen Senior Vice President The.
Health Care Reform and Its Impact on EMS: Volume to Value, Improving Population Health and Other Paradigm Shifts.

Health Care Reform and Its Impact on EMS: Volume to Value, Improving Population Health and Other Paradigm Shifts.
Patient Centered Medical Home Program. Blue Cross Blue Shield of Montana PCMH Overview Began as a pilot PCMH program in late 2009 to correct gaps in care.

Patient Centered Medical Home Program. Blue Cross Blue Shield of Montana PCMH Overview Began as a pilot PCMH program in late 2009 to correct gaps in care.
MEDICARE: PAST, PRESENT AND F UTURE James G. Anderson, Ph.D. Department of Sociology & Anthropology.

MEDICARE: PAST, PRESENT AND F UTURE James G. Anderson, Ph.D. Department of Sociology & Anthropology.
HCMDSS November 16-17, 2004 Arlington, VA Victoria L. Rich, PhD, RN Chief Nursing Officer Hospital of the University of Pennsylvania Assistant Dean of.

HCMDSS November 16-17, 2004 Arlington, VA Victoria L. Rich, PhD, RN Chief Nursing Officer Hospital of the University of Pennsylvania Assistant Dean of.
COC ADVOCACY TRACK Overview of National Oncology Issues & Key COA Initiatives for 2015 Ted Okon Orlando, Florida April 23, 2015.

COC ADVOCACY TRACK Overview of National Oncology Issues & Key COA Initiatives for 2015 Ted Okon Orlando, Florida April 23, 2015.
Trends In Health Care Industry KNH 413. Difficult questions What is health insurance? What is health care versus health insurance? Is one or both a right.

Trends In Health Care Industry KNH 413. Difficult questions What is health insurance? What is health care versus health insurance? Is one or both a right.
8710.736-503 The Facts About Rising Health Care Costs.

The Facts About Rising Health Care Costs.
1 Managed Care Digest Series ®, © 2013 sanofi-aventis U.S., A SANOFI COMPANY Data source: IMS Health © 2013 US.NMH.13.02.033 Practice and Hospital Site.

1 Managed Care Digest Series ®, © 2013 sanofi-aventis U.S., A SANOFI COMPANY Data source: IMS Health © 2013 US.NMH Practice and Hospital Site.
Care Delivery in RI Now, and A Look Ahead May 2015 Gus Manocchia, MD Senior Vice President & Chief Medical Officer BCBSRI.

Care Delivery in RI Now, and A Look Ahead May 2015 Gus Manocchia, MD Senior Vice President & Chief Medical Officer BCBSRI.
Major Areas of Health Research Topics Using MEPS Data Access Access Use Use Expenditures Expenditures Health insurance Health insurance Health status and.

Major Areas of Health Research Topics Using MEPS Data Access Access Use Use Expenditures Expenditures Health insurance Health insurance Health status and.
Healthcare Reforms and Pharmaceuticals Lessons from Turkey Prof. Dr. Mehtap Tatar Hacettepe University Faculty of Economics and Administrative Sciences.

Healthcare Reforms and Pharmaceuticals Lessons from Turkey Prof. Dr. Mehtap Tatar Hacettepe University Faculty of Economics and Administrative Sciences.
The Business Case for Bidirectional Integrated Care: Mental Health and Substance Use Services in Primary Care Settings and Primary Care Services in Specialty.

The Business Case for Bidirectional Integrated Care: Mental Health and Substance Use Services in Primary Care Settings and Primary Care Services in Specialty.
Systems Engineering Research and the Cancer Care Engineering Project Joseph F. Pekny, Ph. D. (Purdue University) Professor of Chemical Engineering Interim.

Systems Engineering Research and the Cancer Care Engineering Project Joseph F. Pekny, Ph. D. (Purdue University) Professor of Chemical Engineering Interim.
Health Policy Seminar on Sunday, April 19 th, 2009 Washington, D.C. Shannon Brownlee Visiting Scholar, NIH Clinical Center Dept. of Bioethics Schwartz.

Health Policy Seminar on Sunday, April 19 th, 2009 Washington, D.C. Shannon Brownlee Visiting Scholar, NIH Clinical Center Dept. of Bioethics Schwartz.
Community Oncology Conference Thursday April 23 rd, 2015.

Community Oncology Conference Thursday April 23 rd, 2015.
The Impact of National Health Reform on Adults with Mental Disorders Rachel L. Garfield, Ph.D. Department of Health Policy & Management, University of.

The Impact of National Health Reform on Adults with Mental Disorders Rachel L. Garfield, Ph.D. Department of Health Policy & Management, University of.
Some Observations on Controlling Hospital and Health Care Spending Stuart Guterman Vice President, Medicare and Cost Control The Commonwealth Fund UMBC.

Some Observations on Controlling Hospital and Health Care Spending Stuart Guterman Vice President, Medicare and Cost Control The Commonwealth Fund UMBC.
November 04, 2008 The Price of Medical Technology: The Industry Perspective David H. Nexon Senior Executive Vice President.

November 04, 2008 The Price of Medical Technology: The Industry Perspective David H. Nexon Senior Executive Vice President.
In 2003, Medicaid spent $33.7 billion on drugs (19% of national spending for drugs and more than 10% of the Medicaid budget) Medicaid expenditures ($ billions)

In 2003, Medicaid spent $33.7 billion on drugs (19% of national spending for drugs and more than 10% of the Medicaid budget) Medicaid expenditures ($ billions)

Similar presentations

Ads by Google